Biopharma executives were hammered with questions about drug pricing concerns in the US during January's 34th Annual J.P. Morgan Healthcare Conference in San Francisco and now – five months later in the same city for the Biotechnology Innovation Organization (BIO) International Convention – they appear prepared to strike back with a united message: all stakeholders must work together.
OncoMed Pharmaceuticals Inc. Chairman and CEO Paul Hastings, who is a member of BIO's executive committee and vice chair...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
